EUVIMEDEUVIMED entdecken
Open Access

Pharmacogenetic Profiling of Cytochrome P450 Enzymes in Plasmodium vivax Patients Treated with Chloroquine and Primaquine: Implications for Personalized Malaria Therapy

Papichaya Phompradit, Phunuch Muhamad, Anurak Cheoymang, Kesara Na-Bangchang

The American Journal of Tropical Medicine and Hygiene · 2026

DOI: 10.4269/ajtmh.25-0612 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The American Journal of Tropical Medicine and Hygiene, 2026. Verfasst von Papichaya Phompradit und 3 weiteren Autor:innen. Beteiligte Einrichtung: Chulabhorn International College of Medicine, Thammasat University, Pathum Thani, Thailand. Hauptthemen laut MEDLINE: Primaquine, Chloroquine, Malaria, Vivax, Antimalarials. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

This study aimed to investigate the impact of common polymorphisms in key cytochrome P450 ( CYP ) genes ( CYP2C8 , CYP2C9, CYP2C19 , CYP2D6 , and CYP3A5 ) on drug levels and treatment responses in Plasmodium vivax -infected patients treated with chloroquine (CQ) and primaquine (PQ). CYP2C8 and CYP3A5 are the key enzymes that metabolize CQ, whereas CYP2D6, CYP2C9, and CYP2C19 are those that metabolize PQ. A total of 99 DNA samples from Burmese patients with microscopically confirmed P. vivax monoinfection, who received standard doses of CQ (25 mg/kg) and PQ (15 mg/kg/day for 14 days), were included for genotyping of CYP polymorphisms using polymerase chain reaction-restriction fragment length polymorphism assays. The relationship between CYP polymorphisms and patients’ clinical outcomes and drug level data was assessed. All patients achieved complete parasite clearance and resolution of fever without recurrence. The most frequent alleles were CYP3A5*3 (71.7%) and CYP2D6*10 (30.6%). The CYP3A5*3 variant was significantly associated with altered desethylchloroquine levels, whereas CYP2C19*3 was associated with faster parasite clearance. No significant associations were found between CYP2D6 or CYP2C8 variants and PQ levels or clinical efficacy. Notably, a patient homozygous for CYP2D6 * 4 (a poor metabolizer) responded successfully to treatment, suggesting the presence of alternative or compensatory metabolic pathways. Despite a high prevalence of reduced-function CYP variants, CQ-PQ therapy was effective in all patients, indicating that genetic polymorphisms may influence drug metabolism without compromising clinical outcomes. Nevertheless, CYP3A5*3 and CYP2C19 * 3 variants appear to modulate drug pharmacokinetics and parasite clearance kinetics. These findings underscore the importance of pharmacogenetic surveillance to optimize antimalarial therapy, particularly in elimination settings.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

PrimaquineChloroquineMalaria, VivaxAntimalarialsPlasmodium vivaxCytochrome P-450 Enzyme SystemHumansMaleFemaleAdultAdolescentYoung AdultMiddle AgedCytochrome P-450 CYP2C19GenotypePolymorphism, GeneticPrecision MedicineCytochrome P-450 CYP2C8Cytochrome P-450 CYP2D6Cytochrome P-450 CYP3A

Substanzen

PrimaquineChloroquineAntimalarialsCytochrome P-450 Enzyme SystemCytochrome P-450 CYP2C19Cytochrome P-450 CYP2C8Cytochrome P-450 CYP2D6CYP3A5 protein, humanCYP2C19 protein, humanCytochrome P-450 CYP3A

Autor:innen und Institutionen

  • Chulabhorn International College of Medicine, Thammasat University, Pathum Thani, Thailand.
  • Drug Discovery and Development Center, Office of Advanced Science and Technology, Thammasat University, Pathum Thani, Thailand.
  • Faculty of Allied Health Sciences, Thammasat University, Pathum Thani, Thailand.
  • Center of Excellence in Pharmacology and Molecular Biology of Malaria and Cholangiocarcinoma, Chulabhorn International College of Medicine, Thammasat University, Pathum Thani, Thailand.
  • Graduate Program in Bioclinical Sciences, Chulabhorn International College of Medicine, Thammasat University, Pathum Thani, Thailand.

Zitieren

APA

Phompradit, P., Muhamad, P., Cheoymang, A., & Na-Bangchang, K. (2026). Pharmacogenetic Profiling of Cytochrome P450 Enzymes in Plasmodium vivax Patients Treated with Chloroquine and Primaquine: Implications for Personalized Malaria Therapy. The American Journal of Tropical Medicine and Hygiene. https://doi.org/10.4269/ajtmh.25-0612

Vancouver

Phompradit P, Muhamad P, Cheoymang A, Na-Bangchang K. Pharmacogenetic Profiling of Cytochrome P450 Enzymes in Plasmodium vivax Patients Treated with Chloroquine and Primaquine: Implications for Personalized Malaria Therapy. The American Journal of Tropical Medicine and Hygiene. 2026. doi:10.4269/ajtmh.25-0612

BibTeX
@article{Phompradit2026,
  author = {Phompradit, Papichaya and Muhamad, Phunuch and Cheoymang, Anurak and Na-Bangchang, Kesara},
  title = {Pharmacogenetic Profiling of Cytochrome P450 Enzymes in Plasmodium vivax Patients Treated with Chloroquine and Primaquine: Implications for Personalized Malaria Therapy},
  journal = {The American Journal of Tropical Medicine and Hygiene},
  year = {2026},
  doi = {10.4269/ajtmh.25-0612}
}
Kostenlos starten →